BRPI0708471A2 - métodos para inibir a atividade de uma protease de tipo catepsina l em células ou tecido, para inibir a superexpressão de uma protease de tipo catepsina l em células ou tecido, e para tratar uma condição associada com atividade aberrante e/ou superexpressão de uma protease de tipo catepsina l em um paciente, propeptìdeo de catepsina ou um ácido nucleico codificando um propeptìdeo de catepsina, uso de propeptìdeo de catepsina ou de um ácido nucleico codificando um propeptìdeo de catepsina, composição farmacêutica, e, método para produção recombinante de propeptìdeos de catepsina - Google Patents

métodos para inibir a atividade de uma protease de tipo catepsina l em células ou tecido, para inibir a superexpressão de uma protease de tipo catepsina l em células ou tecido, e para tratar uma condição associada com atividade aberrante e/ou superexpressão de uma protease de tipo catepsina l em um paciente, propeptìdeo de catepsina ou um ácido nucleico codificando um propeptìdeo de catepsina, uso de propeptìdeo de catepsina ou de um ácido nucleico codificando um propeptìdeo de catepsina, composição farmacêutica, e, método para produção recombinante de propeptìdeos de catepsina Download PDF

Info

Publication number
BRPI0708471A2
BRPI0708471A2 BRPI0708471-4A BRPI0708471A BRPI0708471A2 BR PI0708471 A2 BRPI0708471 A2 BR PI0708471A2 BR PI0708471 A BRPI0708471 A BR PI0708471A BR PI0708471 A2 BRPI0708471 A2 BR PI0708471A2
Authority
BR
Brazil
Prior art keywords
cathepsin
propeptide
protease
nucleic acid
cells
Prior art date
Application number
BRPI0708471-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher Scott
Roberta Burden
Jim Johnston
Mark Mccurley
Philip Snoddy
Richard Buick
Original Assignee
Fusion Antibodies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Antibodies Ltd filed Critical Fusion Antibodies Ltd
Publication of BRPI0708471A2 publication Critical patent/BRPI0708471A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0708471-4A 2006-03-02 2007-03-02 métodos para inibir a atividade de uma protease de tipo catepsina l em células ou tecido, para inibir a superexpressão de uma protease de tipo catepsina l em células ou tecido, e para tratar uma condição associada com atividade aberrante e/ou superexpressão de uma protease de tipo catepsina l em um paciente, propeptìdeo de catepsina ou um ácido nucleico codificando um propeptìdeo de catepsina, uso de propeptìdeo de catepsina ou de um ácido nucleico codificando um propeptìdeo de catepsina, composição farmacêutica, e, método para produção recombinante de propeptìdeos de catepsina BRPI0708471A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0604187.5A GB0604187D0 (en) 2006-03-02 2006-03-02 Peptide and uses thereof
GB0604187.5 2006-03-02
PCT/GB2007/000744 WO2007099348A2 (fr) 2006-03-02 2007-03-02 Peptide et ses utilisations

Publications (1)

Publication Number Publication Date
BRPI0708471A2 true BRPI0708471A2 (pt) 2011-05-31

Family

ID=36218985

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0708471-4A BRPI0708471A2 (pt) 2006-03-02 2007-03-02 métodos para inibir a atividade de uma protease de tipo catepsina l em células ou tecido, para inibir a superexpressão de uma protease de tipo catepsina l em células ou tecido, e para tratar uma condição associada com atividade aberrante e/ou superexpressão de uma protease de tipo catepsina l em um paciente, propeptìdeo de catepsina ou um ácido nucleico codificando um propeptìdeo de catepsina, uso de propeptìdeo de catepsina ou de um ácido nucleico codificando um propeptìdeo de catepsina, composição farmacêutica, e, método para produção recombinante de propeptìdeos de catepsina

Country Status (9)

Country Link
US (1) US20100104554A1 (fr)
EP (1) EP2001505A2 (fr)
JP (1) JP2009528339A (fr)
CN (1) CN101432014A (fr)
AU (1) AU2007220307A1 (fr)
BR (1) BRPI0708471A2 (fr)
CA (1) CA2643723A1 (fr)
GB (1) GB0604187D0 (fr)
WO (1) WO2007099348A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3492488A1 (fr) 2007-08-22 2019-06-05 The Regents of The University of California Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci
GB0816561D0 (en) * 2008-09-10 2008-10-15 Fusion Antibodies Ltd Peptides and uses thereof
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
WO2014059384A2 (fr) * 2012-10-12 2014-04-17 University Of Southern California Elp ciblant icam-1
US11464867B2 (en) 2018-02-13 2022-10-11 University Of Southern California Multimeric elastin-like polypeptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5710014A (en) * 1988-02-11 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Cloned cDNA for human procathepsin l.
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5501969A (en) * 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
DE19619366A1 (de) * 1996-05-14 1997-11-20 Hoechst Ag Cathepsin-L, dessen Präpoform und das entsprechende Propeptid aus Ciliaten
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP2002517208A (ja) * 1998-06-04 2002-06-18 リプロゲン，インコーポレイティド 子宮内膜症の診断および治療におけるカテプシンの使用
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20030143714A1 (en) * 2001-10-19 2003-07-31 Medivir Uk Ltd. Crystal structure of a mutant of cathepsin S enzyme
WO2003097664A2 (fr) * 2002-05-15 2003-11-27 National Research Council Of Canada Inhibiteurs de cysteine proteases a base de propeptides

Also Published As

Publication number Publication date
CN101432014A (zh) 2009-05-13
US20100104554A1 (en) 2010-04-29
WO2007099348A3 (fr) 2007-11-08
EP2001505A2 (fr) 2008-12-17
GB0604187D0 (en) 2006-04-12
JP2009528339A (ja) 2009-08-06
WO2007099348A2 (fr) 2007-09-07
AU2007220307A1 (en) 2007-09-07
CA2643723A1 (fr) 2007-09-07

Similar Documents

Publication Publication Date Title
BRPI0708471A2 (pt) métodos para inibir a atividade de uma protease de tipo catepsina l em células ou tecido, para inibir a superexpressão de uma protease de tipo catepsina l em células ou tecido, e para tratar uma condição associada com atividade aberrante e/ou superexpressão de uma protease de tipo catepsina l em um paciente, propeptìdeo de catepsina ou um ácido nucleico codificando um propeptìdeo de catepsina, uso de propeptìdeo de catepsina ou de um ácido nucleico codificando um propeptìdeo de catepsina, composição farmacêutica, e, método para produção recombinante de propeptìdeos de catepsina
Mangione et al. Plasminogen activation triggers transthyretin amyloidogenesis in vitro
Chung et al. Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors
Lankelma et al. Cathepsin L, target in cancer treatment?
Nagata Apoptotic DNA fragmentation
Giffard et al. Many mechanisms for hsp70 protection from cerebral ischemia
Vila et al. Targeting programmed cell death in neurodegenerative diseases
JP5566105B2 (ja) 感染症に対する候補薬
US20210260205A1 (en) Cartilage-homing peptide conjugates and methods of use thereof
Couture et al. On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications
Kryczka et al. Proteases revisited: roles and therapeutic implications in fibrosis
Xie et al. Cathepsin B in programmed cell death machinery: mechanisms of execution and regulatory pathways
Jackson et al. Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase
US7374898B2 (en) Peptide inhibitors against seprase
JP2020186263A (ja) 放射性および化学的損傷を予防及び治療するための方法
Kreuter et al. Stroke, myocardial infarction, acute and chronic inflammatory diseases: caspases and other apoptotic molecules as targets for drug development
EP2822546B1 (fr) Procaspase polythérapie pour le traitement du cancer
Loeffler Experimental approaches for altering the expression of Abeta‐degrading enzymes
Zhang et al. Evaluation of conditions for calpain inhibition in the rat spinal cord: effective postinjury inhibition with intraspinal MDL28170 microinjection
JP2005536453A (ja) 部分的なペプチド擬似物及び方法
US8017747B2 (en) Apoptosis-inducing genes for treating cancer
EP3341389B1 (fr) Inhibiteurs peptidiques de translocation de la télomérase et leurs utilisations thérapeutiques
Zhang et al. The role of caspase family in acute brain injury: the potential therapeutic targets in the future
JP2012503015A (ja) カルパイン阻害のための方法、系および組成物
US20080280824A1 (en) Compositions and methods for treatment of cancer or neurodegenerative disease with peptide based microtubule stabilizers or inhibitors

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2224 DE 20/08/2013.

B11T Dismissal of application maintained [chapter 11.20 patent gazette]